MOLN Molecular Partners

Molecular Partners to Participate in the TD Cowen 7th Annual Fall Oncology Innovation Summit

Molecular Partners to Participate in the TD Cowen 7th Annual Fall Oncology Innovation Summit

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) --  AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that the Company will participate in a fireside chat at the TD Cowen 7th Annual Fall Oncology Innovation Summit on Friday, November 3, 2023 at 9:00 a.m. ET. Presenting on behalf of Molecular Partners will be Patrick Amstutz, Chief Executive Officer, and Dr. Philippe Legenne, acting CMO.  

A live webcast of the event will be available on the "News and Events" page in the "Events" section of the . A replay of the webcast will be archived on the Company's website for 90 days following the presentation date.

About Molecular Partners AG  

Molecular Partners AG is a clinical-stage biotech company developing DARPin (designed ankyrin repeat protein) therapeutics, a new class of custom-built protein drugs designed to address challenges current modalities cannot. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics in the areas of oncology and virology and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.  

Find us on Twitter - 



For further details, please contact: 

Seth Lewis, SVP Investor Relations & Strategy 

Concord, Massachusetts, U.S. 

 

Tel:  

Laura Jeanbart, PhD, Head of Portfolio Management & Communications  

Zurich-Schlieren, Switzerland 

  

Tel: 5



EN
01/11/2023

Underlying

MOLNMolecular Partners

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Molecular Partners

 PRESS RELEASE
Free
MOLN Molecular Partn...

Molecular Partners to Present at Upcoming Investor Conferences

Molecular Partners to Present at Upcoming Investor Conferences ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 19, 2025 (GLOBE NEWSWIRE) --  AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced that members of the management team will participate in two upcoming investor conferences. H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ: Fireside Chat on Tuesday May 20, 2025 beginning at 3:30pm ET TD Cowen’s 6th Annual...

May 19, 2025 1 EN
 PRESS RELEASE
Free
MOLN Molecular Partn...

Molecular Partners Reports Financial Results and Highlights from Q1 20...

Molecular Partners Reports Financial Results and Highlights from Q1 2025 Clinical programs on track, with two major milestones later this year, and cash position, CHF 131 million as of March 31, 2025, expected to provide funding well into 2027IND filing and initial clinical data on first targeted Radio-DARPin therapy program, MP0712, expected in 2025; strategic partnership with Orano Med expanded from four to ten programsData from dosing cohort 8 in Phase 1/2a trial of MP0533 demonstrate increased rates and depth of responses; study protocol amendment now approved, and dosing cohort 9 enrol...

May 15, 2025 1 EN
 PRESS RELEASE
Free
MOLN Molecular Partn...

Molecular Partners presents new preclinical data on Radio-DARPin and S...

Molecular Partners presents new preclinical data on Radio-DARPin and Switch-DARPin programs at AACR 2025 Positive IND-enabling data on MP0712 targeting DLL3, the most advanced Radio-DARPin program in co-development with Orano Med, entering clinical development in 2025 First preclinical data of novel targeted Radio-DARPin against mesothelin (MSLN), in co-development with Orano Med Additional preclinical proof-of-concept data on logic-gated CD3 Switch-DARPin T cell engager with CD2 co-stimulation ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., April 25, 2025 (GLOBE NEWSWIRE) -- Ad ...

April 25, 2025 1 EN
 PRESS RELEASE
Free
MOLN Molecular Partn...

Molecular Partners Announces all Board Proposals Approved at Annual Ge...

Molecular Partners Announces all Board Proposals Approved at Annual General Meeting ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., April 16, 2025 (GLOBE NEWSWIRE) -- AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced that all motions proposed by the Board of Directors at the Annual General meeting were approved by the shareholders of the Company by a wide majority. The Molecular Partners shareholders confirmed the approval of the annua...

April 16, 2025 1 EN
 PRESS RELEASE
Free
MOLN Molecular Partn...

Molecular Partners to hold three poster presentations at AACR 2025

Molecular Partners to hold three poster presentations at AACR 2025 Update on IND-enabling data for MP0712, a Radio-DARPin targeting DLL3 and labeled with 212Pb, co-developed with Orano Med; entering FIH studies in 2025 for the treatment of small cell lung cancer First preclinical data on second 212Pb-based Radio-DARPin co-developed with Orano Med, targeting the membrane-proximal region of mesothelin (MSLN) in solid tumors Additional preclinical proof-of-concept data on CD3 Switch-DARPin T cell engager with CD2 co-stimulation in solid tumors ZURICH-SCHLIEREN, Switzerland and CONCORD, Mas...

March 25, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch